Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000902664-25-002479
Filing Date
2025-05-19
Accepted
2025-05-19 16:35:51
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 7574
  Complete submission text file 0000902664-25-002479.txt   9440
Mailing Address 3 PLEASANT STREET, SUITE 400 C/O MATRIX CAPITAL MANAGEMENT PORTSMOUTH NH 03801
Business Address 3 PLEASANT STREET, SUITE 400 C/O MATRIX CAPITAL MANAGEMENT PORTSMOUTH NH 03801 781-522-4948
Matrix Capital Management Company, LP (Filed by) CIK: 0001410830 (see all company filings)

EIN.: 043475951 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A

Mailing Address 80 GUEST STREET BOSTON MA 02135
Business Address 80 GUEST STREET BOSTON MA 02135 (617)500-8864
Aura Biosciences, Inc. (Subject) CIK: 0001501796 (see all company filings)

EIN.: 320271970 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-92997 | Film No.: 25964542
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)